Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6271 to 6285 of 8789 results

  1. Allogeneic stem cell transplantation:- What is the effectiveness of combined autologous–allogeneic stem cell transplantation compared with autologous stem cell transplantation, plus consolidation and maintenance treatment in chemosensitive patients at first response or first relapse?

    Recommendation ID NG35/4 Question Allogeneic stem cell transplantation:- What is the effectiveness of combined autologous–allogeneic stem

  2. Bisphosphonates for the prevention of bone disease:- What is the effectiveness of monthly zoledronic acid given indefinitely compared with zoledronic acid given for a fixed duration in patients with myeloma?

    Recommendation ID NG35/5 Question Bisphosphonates for the prevention of bone disease:- What is the effectiveness of monthly zoledronic

  3. Current evidence on the safety and efficacy of bronchoscopic thermal vapour ablation for upper-lobe emphysema is inadequate in quantity and quality. Therefore the procedure should only be used in the context of  research .

    Recommendation ID IPG652/1 Question Current evidence on the safety and efficacy of bronchoscopic thermal vapour ablation for upper-lobe

  4. Cachexia interventions: - A cohort study followed by phase II and III studies should be undertaken in people with pancreatic cancer and cachexia or pre-cachexia, to compare cachexia assessment methods and anti-cachexia interventions with standard care.

    Recommendation ID NG85/2 Question Cachexia interventions: - A cohort study followed by phase II and III studies should be undertaken in

  5. NICE joins international collaboration on HTA methods research

    We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) to establish the Health Economics Methods Advisory (HEMA), a new international initiative to research and evaluate health technology assessment (HTA) methods.

  6. International collaboration provides new guidance on the use of surrogate endpoints in cost-effectiveness analysis

    Recommendations will help organisations that evaluate new drugs establish whether their use will result in longer-term benefits for patients

  7. Patients to get new medicines up to 6 months sooner

    A new aligned pathway between NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) will help bring medicines to patients faster.

  8. Saving babies' hearing: how a world-first rapid genetic test is transforming neonatal care

    Learn how NICE's healthtech guidance helped bring life-changing genetic testing to neonatal units across the UK, saving 20 babies' hearing so far with potential to prevent hearing loss in 200 babies annually.

  9. NICE recommends life changing technology is rolled out to people with type 1 diabetes

    Thousands of people with type 1 diabetes could be offered wearable technology to help them manage their condition following the publication of final draft guidance by NICE.

  10. MHRA-NICE pathway opens for business – everything you need to know to get started

    Learn how the MHRA and NICE are getting medicines to patients 3 to 6 months sooner by delivering same time decisions on licensing and value.

  11. Backing the healthtech that changes lives

    Home News Podcasts Backing the healthtech that changes lives Podcasts 31 March 2026 Listen About this episode When the right technology reaches